Keel Point, LLC Avadel Pharmaceuticals PLC Transaction History

Keel Point, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.07 - $6.95 $15,588 - $101,254	-14,569 Closed	0 $0
Q4 2021 Jan 31, 2022	SELL	$7.34 - $11.18 $304,610 - $463,970	-41,500 Reduced 74.02%	14,569 $117,000
Q3 2021 Nov 04, 2021	BUY	$6.49 - $9.91 $363,887 - $555,643	56,069 New	56,069 $549,000
Q2 2021 Aug 06, 2021	BUY	$6.73 - $9.05 $434,549 - $584,349	64,569 Added 149.98%	107,620 $724,000
Q2 2021 Aug 06, 2021	SELL	$6.73 - $9.05 $724,282 - $973,961	-107,620 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$6.61 - $10.07 $325,033 - $495,172	-49,173 Reduced 53.32%	43,051 $389,000
Q3 2020 Nov 18, 2020	BUY	$5.02 - $8.98 $100,399 - $179,600	20,000 Added 27.69%	92,224 $465,000
Q2 2020 Aug 14, 2020	BUY	$7.25 - $11.75 $11,244 - $18,224	1,551 Added 2.19%	72,224 $584,000
Q1 2020 May 01, 2020	BUY	$4.06 - $10.64 $124,532 - $326,360	30,673 Added 76.68%	70,673 $561,000
Q4 2019 Feb 07, 2020	BUY	$3.34 - $7.7 $133,600 - $308,000	40,000 New	40,000 $302,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Keel Point, LLC, based on Form 13F filings with the SEC.

Stay updated on Keel Point, LLC with notifications on news.